| 3 | Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer. (Uyar D, Neary J, Monroe A, Nugent M, Simpson P, Geurts JL) Gynecol Oncol 2018 Jun;149(3):565-569 23 Citations |
| 1 | A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. (Thaker PH, Brady WE, Lankes HA, Odunsi K, Bradley WH, Moore KN, Muller CY, Anwer K, Schilder RJ, Alvarez RD, Fracasso PM) Gynecol Oncol 2017 Nov;147(2):283-290 57 Citations |
| 1 | Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. (Cohn DE, Sill MW, Walker JL, O'Malley D, Nagel CI, Rutledge TL, Bradley W, Richardson DL, Moxley KM, Aghajanian C) Gynecol Oncol 2017 Sep;146(3):477-483 74 Citations |
| 3 | Sucrose Non-Fermenting Related Kinase Expression in Ovarian Cancer and Correlation with Clinical Features. (Hopp EE, Cossette SM, Kumar SN, Eastwood D, Ramchandran R, Bishop E) Cancer Invest 2017 Aug 09;35(7):456-462 6 Citations |
| 1 | A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. (Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G) Ann Oncol 2017 May 01;28(5):996-1004 89 Citations |
| 2 | Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. (Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Ram P, Liu J, Lu Y, Lopez-Berestein G, Calin GA, Sood AK, Mills GB) Cell Rep 2016 May 17;15(7):1493-1504 89 Citations |
| 2 | Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. (Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, Børresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GB) Cancer Cell 2014 Dec 08;26(6):863-879 50 Citations |
| 2 | Hematogenous metastasis of ovarian cancer: rethinking mode of spread. (Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK) Cancer Cell 2014 Jul 14;26(1):77-91 278 Citations |
| 1 | Lessons from miR-143/145: the importance of cell-type localization of miRNAs. (Kent OA, McCall MN, Cornish TC, Halushka MK) Nucleic Acids Res 2014 Jul;42(12):7528-38 180 Citations |
| 1 | Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. (Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R) Clin Cancer Res 2012 Oct 15;18(20):5796-805 80 Citations |
| 1 | Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model. (Moore RG, Lange TS, Robinson K, Kim KK, Uzun A, Horan TC, Kawar N, Yano N, Chu SR, Mao Q, Brard L, DePaepe ME, Padbury JF, Arnold LA, Brodsky A, Shen TL, Singh RK) PLoS One 2012;7(4):e34443 18 Citations |
| 1 | Overcoming platinum resistance through the use of a copper-lowering agent. (Fu S, Naing A, Fu C, Kuo MT, Kurzrock R) Mol Cancer Ther 2012 Jun;11(6):1221-5 76 Citations |
| 1 | Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. (Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC Jr, Mills GB) Gynecol Oncol 2012 Jul;126(1):47-53 69 Citations |
| 1 | Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. (Barlin JN, Yu C, Hill EK, Zivanovic O, Kolev V, Levine DA, Sonoda Y, Abu-Rustum NR, Huh J, Barakat RR, Kattan MW, Chi DS) Gynecol Oncol 2012 Apr;125(1):25-30 58 Citations |
| 1 | Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. (Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC Jr) Cancer 2011 Apr 15;117(8):1661-9 164 Citations |
| 2 | Pten in stromal fibroblasts suppresses mammary epithelial tumours. (Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, Creasap N, Thompson JC, Caserta E, Wang H, Chong JL, Naidu S, Wei G, Sharma SM, Stephens JA, Fernandez SA, Gurcan MN, Weinstein MB, Barsky SH, Yee L, Rosol TJ, Stromberg PC, Robinson ML, Pepin F, Hallett M, Park M, Ostrowski MC, Leone G) Nature 2009 Oct 22;461(7267):1084-91 465 Citations |
| 1 | Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model. (Gong J, Yang DJ, Kohanim S, Angelo LS, Kurzrock R) Cancer Biol Ther 2009 Dec;8(23):2239-47 2 Citations |
| 1 | Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. (Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, Mutch DG, Powell MA) Cancer 2006 Jul 01;107(1):83-9 124 Citations |
| 1 | Tumor-associated alterations in caspase-14 expression in epithelial malignancies. (Krajewska M, Kim H, Shin E, Kennedy S, Duffy MJ, Wong YF, Marr D, Mikolajczyk J, Shabaik A, Meinhold-Heerlein I, Huang X, Banares S, Hedayat H, Reed JC, Krajewski S) Clin Cancer Res 2005 Aug 01;11(15):5462-71 63 Citations |
| 1 | Expression and localization of GRP75 in human epithelial tumors and normal tissues. (Srokowski T, Pfeifer JD, Li J, Olson LM, Rader JS) Appl Immunohistochem Mol Morphol 2004 Jun;12(2):132-8 7 Citations |
| 1 | Topotecan in platinum- and paclitaxel-resistant ovarian cancer. (Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ) Gynecol Oncol 1997 Sep;66(3):480-6 147 Citations |
